Adding Adjuvant Iriniotecan to 5FU/LV Not Effective for Resected Rectal Cancer

Share this content:
Postoperative irinotecan should not be added to a fluorouracil plus leucovorin regimen for treatment of rectal cancer.
Postoperative irinotecan should not be added to a fluorouracil plus leucovorin regimen for treatment of rectal cancer.

According to a new study published online in the journal Annals of Oncology, researchers have found that postoperative irinotecan should not be added to a fluorouracil plus leucovorin adjuvant regimen for the treatment of patients with optimally resected stage II-III rectal cancer.

For the study, researchers enrolled 357 patients with stage II-III rectal cancer who underwent surgery to remove the tumor between March 1999 and December 2005. Patients were randomly assigned to receive flurouracil plus leucovorin with or without irinotecan.

Results showed that with a follow-up of 156 months, the disease-free survival was in favor of the irinotecan arm but did not reach statistical significance (HR = 0.80; P = 0.154).

Overall survival also favored the experimental arm but did not reach statistical significance either (HR = 0.87; P = 0.433).

RELATED: Treatment Patterns Vary by Hospital for Metastatic Colorectal Cancer

Researchers found that the 5-year disease-free survival was 58% in the fluorouracil/leucovorin only arm and 63% in the irinotecan arm.

The 5-year overall survival was 74% and 75% in the control arm and experimental arm, respectively.

In regard to safety, patients who received irinotecan experienced more neutropenia and diarrhea compared with the control arm.

Reference

  1. Delbaldo C, Ychou M, Zawadi A, et al. Postoperative irinotecan in resected stage II-III rectal cancer. Final analysis of the French R98 intergroup trial. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv135.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs